Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

2.

New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies.

Dogliotti I, Drandi D, Genuardi E, Ferrero S.

J Clin Med. 2018 Sep 18;7(9). pii: E288. doi: 10.3390/jcm7090288. Review.

3.

Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia.

Drandi D, Genuardi E, Dogliotti I, Ferrante M, Jiménez C, Guerrini F, Schirico ML, Mantoan B, Muccio V, Lia G, Zaccaria GM, Omedè P, Passera R, Orsucci L, Benevolo G, Cavallo F, Galimberti S, Sanz RG, Boccadoro M, Ladetto M, Ferrero S.

Haematologica. 2018 Jun;103(6):1029-1037. doi: 10.3324/haematol.2017.186528. Epub 2018 Mar 22.

4.

A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma.

Ghione P, Cavallo F, Visco C, Chen Z, Castellino A, Tisi MC, Dogliotti I, Nicolosi M, Boccadoro M, Leonard JP, Vitolo U, Martin P.

Br J Haematol. 2018 Dec;183(5):828-831. doi: 10.1111/bjh.15057. Epub 2017 Dec 19. No abstract available.

5.

Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis.

Genuardi E, Barbero D, Dogliotti I, Mantoan B, Drandi D, Gambella M, Zaccaria GM, Monitillo L, Della Starza I, Cavalli M, De Novi LA, Ciabatti E, Grassi S, Gazzola A, Mannu C, Del Giudice I, Galimberti S, Agostinelli C, Piccaluga PP, Ladetto M, Ferrero S; Fondazione Italiana Linfomi (FIL) MRD Network.

Int J Lab Hematol. 2018 Apr;40(2):201-208. doi: 10.1111/ijlh.12766. Epub 2017 Dec 4.

PMID:
29205868
6.

CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.

Dogliotti I, Fava C, Serra A, Gottardi E, Daraio F, Carnuccio F, Giugliano E, Bocchia M, Saglio G, Rege-Cambrin G.

Stem Cell Investig. 2017 Jun 23;4:57. doi: 10.21037/sci.2017.06.02. eCollection 2017.

7.

Diagnosis of del(5q) MDS, 14 Years after JAK-2 Positive PV Appearance: Complete Remission of both Diseases with Lenalidomide Monotherapy.

Vaccarino A, Dogliotti I, Marletto F, Demarchi A, Bazzan M.

Mediterr J Hematol Infect Dis. 2016 Oct 20;8(1):e2016050. eCollection 2016.

8.

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.

Fava C, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchialla P, Di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S96-S100. doi: 10.1016/j.clml.2016.03.008. Epub 2016 Apr 1. Review.

PMID:
27131622
9.

Update on emerging treatments for chronic myeloid leukemia.

Fava C, Morotti A, Dogliotti I, Saglio G, Rege-Cambrin G.

Expert Opin Emerg Drugs. 2015 Jun;20(2):183-96. doi: 10.1517/14728214.2015.1031217. Epub 2015 Mar 31. Review.

PMID:
25826695

Supplemental Content

Loading ...
Support Center